🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsPublic SquareAlcohol metabolism changes on semaglutide — July 2024

Alcohol metabolism changes on semaglutide — July 2024

LondonLisa Tue, Nov 4, 2025 at 9:42 AM 12 replies 1,199 viewsPage 1 of 3
This thread is more than 7 months old. Information may be outdated. Consider searching for more recent discussions.
LondonLisa
Member
912
3,456
Mar 2024
London, UK
Nov 4, 2025 at 9:42 AM#1

This is the version of the explanation I wish somebody had given me, written down before I forget what confused me. It is about semaglutide, and it is deliberately narrow — everything I am not confident about is marked as such.

What is actually established

The mechanism that matters here is not stomach emptying, it is central. GLP-1 receptor agonism in the arcuate nucleus stimulates POMC neurons and suppresses AgRP/NPY signalling, which is why the effect is appetite and food salience rather than physical fullness. Delayed gastric emptying largely tachyphylaxes over the first months; the appetite effect does not.

The condition it depends on

That holds for the injectable. The oral formulation has different absorption behaviour and the dose numbers are not interchangeable, which is worth saying out loud because people quote them as if they were.

The practical version

For anyone assembling their own picture: Tmax is one to three days, terminal half-life about 165 to 170 hours, steady state at four to five weeks, and subcutaneous bioavailability near 89%. Those four numbers explain most of the questions people ask about timing.

What I am not sure about

The bit I cannot resolve on my own is whether anyone has held at a sub-maximal dose long term and kept the result, or whether the maintenance data only exists at 2.4mg. Numbers rather than impressions, if you have them.

— LondonLisa · corrections welcome and will be edited into this post with credit
35 5SaraMom3, Dr.MetabolicMD, RetaRick_CA and 32 others
Reply Quote Save Share Report
RetaRick_CA
VIP Member
2,012
9,876
Jan 2024
California
Nov 4, 2025 at 10:24 AM#2
LondonLisa said:
The mechanism that matters here is not stomach emptying, it is central.

Agreed, though "tolerable" needs defining. A dose you tolerate by eating almost nothing is not tolerated, it is being paid for somewhere else — usually in lean mass, sometimes in adherence three months later.

Last edited: Nov 4, 2025 at 11:24 AM
34 4AmyNC_wife, SkepticalSean, Dr.CardioMD and 31 others
Reply Quote Save Share Report
PeptideChemSF
Senior Member
1,890
9,012
Jan 2024
San Francisco, CA
Nov 4, 2025 at 11:06 AM#3
LondonLisa said:
The mechanism that matters here is not stomach emptying, it is central.

I will push back on the "any working dose is fine" framing. The maintenance evidence sits overwhelmingly at the top studied dose, and the extension data shows regain tracking dose reduction rather than tracking stopping. Holding low is reasonable; pretending it is evidentially equivalent is not.

33 3FDA_TrackerJim, ricardo_MIA, BrianDallas92 and 30 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
LibrarianMeg
Senior Member
1,678
7,890
Mar 2024
Baltimore, MD
Nov 4, 2025 at 11:48 AM#4

Taking the question as asked, rather than the general version of it. Albumin binding above 99% is the whole reason weekly dosing works, and it is also why the trough matters more than the peak. People who dose late are not losing a peak, they are letting the trough fall, and the appetite effect tracks the trough.

Last edited: Nov 4, 2025 at 1:48 PM
32 2JessicaM_2024, TomFromTexas, mike.trainer_LA and 29 others
Reply Quote Save Share Report
MarkLI_maint
Member
534
2,345
Jun 2024
Long Island, NY
Nov 4, 2025 at 3:45 PM#5
RetaRick_CA said:
Agreed, though "tolerable" needs defining.

All true, with one condition: that curve is for people who reached the dose on schedule. Anyone who slowed the ladder for tolerability is on a different, flatter curve, and comparing yourself with the published mean will make you feel like a non-responder when you are not.

31 1bri_stats, pete_manc_UK, anna.melb_AU and 28 others
Reply Quote Save Share Report

Similar Threads

SELECT trial 4-year follow-up data released — sustained MACE reduction16 replies
GLP-1 receptor agonists and thyroid C-cell concerns — evidence review19 replies
Is there a ceiling effect for GLP-1-mediated weight loss?20 replies
Comparative pharmacokinetics: semaglutide vs tirzepatide vs retatrutide6 replies
My 18-month semaglutide journey — comprehensive data log20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register